{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:17:18Z","timestamp":1776845838752,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":97,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2019]]},"DOI":"10.6061\/clinics\/2019\/e824","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T16:23:00Z","timestamp":1554481380000},"page":"e824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease"],"prefix":"10.1016","volume":"74","author":[{"given":"Luis Eduardo Miani","family":"Gomes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Aparecida Ramos","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-5661","authenticated-orcid":false,"given":"L\u00edvia Bitencourt","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato Lazarin","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-6236","authenticated-orcid":false,"given":"Guilherme","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Gardere","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"de Lourdes Setsuko Ayrizono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Jos\u00e9","family":"Fagundes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-4402","authenticated-orcid":false,"given":"Raquel Franco","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.6061\/clinics\/2019\/e824_bib1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.6061\/clinics\/2019\/e824_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.6061\/clinics\/2019\/e824_bib3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn\u2019s disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.6061\/clinics\/2019\/e824_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12407","article-title":"Review article: a clinician\u2019s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease","volume":"38","author":"Khanna","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.6061\/clinics\/2019\/e824_bib5","first-page":"304","article-title":"Therapeutic drug monitoring in inflammatory bowel disease","volume":"27","author":"Kopylov","year":"2014","journal-title":"Ann Gastroenterol"},{"issue":"2","key":"10.6061\/clinics\/2019\/e824_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/flgastro-2014-100527","article-title":"Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide","volume":"7","author":"Hendy","year":"2016","journal-title":"Frontline Gastroenterol"},{"issue":"9","key":"10.6061\/clinics\/2019\/e824_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.crohns.2012.10.019","article-title":"Infliximab trough levels may predict sustained response to infliximab in patients with Crohn\u2019s disease","volume":"7","author":"Bortlik","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.6061\/clinics\/2019\/e824_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.dld.2013.10.007","article-title":"Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study","volume":"46","author":"Cesarini","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.6061\/clinics\/2019\/e824_bib9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.6061\/clinics\/2019\/e824_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1590\/s0004-2803.201700000-41","article-title":"Importance of measuring levels of infliximab in patients treating inflammatory bowel disease in a Brazilian cohort","volume":"54","author":"Kampa","year":"2017","journal-title":"Arq Gastroenterol"},{"issue":"2","key":"10.6061\/clinics\/2019\/e824_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/apt.14124","article-title":"Infliximab and adalimumab drug levels in Crohn\u2019s disease: contrasting associations with disease activity and influencing factors","volume":"46","author":"Ward","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.6061\/clinics\/2019\/e824_bib12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ibd.21259","article-title":"Monitoring functional serum antitumor necrosis factor antibody level in Crohn\u2019s disease patients who maintained and those who lost response to anti-TNF","volume":"16","author":"Yamada","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.6061\/clinics\/2019\/e824_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study","volume":"65","author":"Yarur","year":"2016","journal-title":"Gut"},{"issue":"8","key":"10.6061\/clinics\/2019\/e824_bib14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3748\/wjg.v23.i8.1489","article-title":"Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn\u2019s disease","volume":"23","author":"Oh","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.6061\/clinics\/2019\/e824_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014581","article-title":"Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"7","author":"Freeman","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.6061\/clinics\/2019\/e824_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ecco-jcc\/jju026","article-title":"High-dose infliximab therapy in Crohn\u2019s disease: clinical experience, safety, and efficacy","volume":"9","author":"Hendler","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.6061\/clinics\/2019\/e824_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cgh.2015.11.014","article-title":"Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis","volume":"14","author":"Papamichael","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.6061\/clinics\/2019\/e824_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.6061\/clinics\/2019\/e824_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.6061\/clinics\/2019\/e824_bib20","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1097\/MIB.0b013e3182a77b41","article-title":"Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study","volume":"19","author":"Paul","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.6061\/clinics\/2019\/e824_bib21","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.6061\/clinics\/2019\/e824_bib22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.6061\/clinics\/2019\/e824_bib23","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"issue":"4","key":"10.6061\/clinics\/2019\/e824_bib24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.6061\/clinics\/2019\/e824_bib25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.6061\/clinics\/2019\/e824_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.6061\/clinics\/2019\/e824_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/apt.13299","article-title":"Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice","volume":"42","author":"Buurman","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.6061\/clinics\/2019\/e824_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17750355","article-title":"Immunogenicity of biologics in inflammatory bowel disease","volume":"11","author":"Vermeire","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"10.6061\/clinics\/2019\/e824_bib29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.6061\/clinics\/2019\/e824_bib30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn\u2019s disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.6061\/clinics\/2019\/e824_bib31","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203893","article-title":"Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.6061\/clinics\/2019\/e824_bib32","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"10.6061\/clinics\/2019\/e824_bib33","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222006627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222006627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:59:33Z","timestamp":1761721173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222006627"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322019000100216&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6445154\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/serum-levels-of-infliximab-and-anti-infliximab-antibodies-in-brazilian-patients-with-crohns-disease\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":33,"alternative-id":["S1807593222006627"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2019\/e824","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2019\/e824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e824"}}